It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT.

The patient continued treatment with omalizumab α (300 mg biweekly subcutaneous injection), voriconazole (200 mg q12h po), and budesonide/formoterol inhalation powder (320/9 µg inhaled bid). The ...

Positive results from the confirmatory clinical efficacy and safety study of ADL-018, proposed biosimilar to XOLAIR® The clinical study met its primary endpoint in Chronic Spontaneous Urticaria ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart, at a 1000 mg dose, administered through a subcutaneous ...

"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients ...

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...

TARRYTOWN, N.Y. and PARIS, June 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the EVEREST Phase 4 trial in adults with ...

SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $6.5 billion biotech company with exceptional financial health according to InvestingPro metrics, announced today that argenx has received ...

Session ID: 2025-07-03:b1d49e73842c4547a2440b2e Player Element ID: vjs_video_3 ...

Dupixent surpassed Xolair in treating CRSwNP and asthma, improving symptoms and quality of life significantly. Quiver AI Summary New findings from the EVEREST Phase 4 trial presented at the 2025 ...